Stockreport

Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares [Canadian Business Journal (Canada)]

Neoleukin Therapeutics, Inc.  (NLTX) 
PDF SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational me [Read more]